Skip to content

Secondary Cancer Risk After Radiation Therapy for Rectal Cancer

Estimation of Second Cancer Risk in Patients Planned With Different Radiotherapy Regimes for Rectal Cancer - A Planning Study and Model-based Analysis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02572362
Enrollment
25
Registered
2015-10-08
Start date
2015-08-31
Completion date
2016-11-30
Last updated
2016-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasms, Second Primary

Brief summary

Retrospective study comparing dose distribution of 3D conformal radiotherapy (3DCRT) and volumetric-modulated arc therapy (VMAT) to estimate secondary cancer risk for patients having had radiation therapy for rectal cancer. Twenty-five patients are included in this study. Planning CT scans are used for comparison of dose distribution and calculation of second cancer risk.

Detailed description

A model-based Analysis calculating the organ-specific excess lifetime attributable risk using the planning CT data sets of 25 patients to estimate second cancer risk for patients after radiotherapy for rectal cancer comparing conventional 3DCRT with VAMT techniques.

Interventions

No Intervention in this retrospective Analysis. All patients included did receive Radiation therapy Independent of this study

Sponsors

Klinik Hirslanden, Zurich
CollaboratorOTHER
Kantonsspital Graubuenden
Lead SponsorOTHER

Study design

Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Male/Female \> 18 years of age * pre or postoperative radiation therapy for rectal cancer * Planning CT

Exclusion criteria

* Planning CT not available

Design outcomes

Primary

MeasureTime frameDescription
Calculation of the organ-specific excess lifetime attributable risk (LAR) (%)60 years (model-based calculation)LAR is calculated for variable Ages at exposure

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026